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Abstract
Background: The tumor suppressor protein p53 is a transcription factor that is mutated in many
cancers. Regulation of gene expression by binding of wild-type p53 to its target sites is accompanied
by changes in epigenetic marks like histone acetylation. We studied DNA binding and epigenetic
changes induced by wild-type and mutant p53 in non-malignant hTERT-immortalized human
mammary epithelial cells overexpressing either wild-type p53 or one of four p53 mutants (R175H,
R249S, R273H and R280K) on a wild-type p53 background.
Results: Using chromatin immunoprecipitation coupled to a 13,000 human promoter microarray,
we found that wild-type p53 bound 197 promoters on the microarray including known and novel
p53 targets. Of these p53 targets only 20% showed a concomitant increase in histone acetylation,
which was linked to increased gene expression, while 80% of targets showed no changes in histone
acetylation. We did not observe any decreases in histone acetylation in genes directly bound by
wild-type p53. DNA binding in samples expressing mutant p53 was reduced over 95% relative to
wild-type p53 and very few changes in histone acetylation and no changes in DNA methylation
were observed in mutant p53 expressing samples.
Conclusion: We conclude that wild-type p53 induces transcription of target genes by binding to
DNA and differential induction of histone acetylation at target promoters. Several new wild-type
p53 target genes, including DGKZ, FBXO22 and GDF9, were found. DNA binding of wild-type p53
is highly compromised if mutant p53 is present due to interaction of both p53 forms resulting in no
direct effect on epigenetic marks.
Background
The wild-type (wt) p53 protein acts as a transcription fac-
tor that responds to a variety of stress stimuli that pose a
threat to normal cells. In response to various genotoxic
stresses, wt p53 binds specific sequence elements in the
promoters of its target genes such as p21, MDM2, PUMA,
and PCNA [1-8]. Binding of wt p53 results in the recruit-
ment of the co-activator p300/CBP and subsequent
acetylation of promoter associated histones H3 and H4
[1,2,6-8]. Binding of this activation complex and
increased histone acetylation was linked to increased
expression of these genes. Activation of wt p53 also causes
repression of a subset of its target genes such as MAP4,
AFP, BCL2, survivin, and various cell cycle regulatory genes
[9-13]. Chromatin immunoprecipitation studies have
shown binding of wt p53 to the promoter regions of some
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of these genes [9-11]. This binding was associated with the
recruitment and binding of the co-repressors SIN3A and
HDAC1, and subsequent decreases in histone H3 and H4
acetylation. Interestingly, gene repression in response to
wt p53 in some cases also requires an interaction with
other DNA binding molecules such as SP1 and the NF-Y
complex [9,10]. Therefore, wt p53 binds the promoters of
its target genes and recruits either co-activators or co-
repressors that modify histone H3 and H4 acetylation lev-
els resulting in hyper-acetylated histones and increased
gene expression [1,2,6,7] or hypo-acetylated histones and
decreased gene expression [9-11]. Since wt p53 transcrip-
tional activity is associated with DNA-binding, a variety of
computational and whole genome chromatin immuno-
precipitation techniques have been utilized to identify
direct p53 target genes [14-20].
p53 protein consists of distinct functional domains
[21,22]. The N-terminal region is involved in transactiva-
tion and the core of the protein forms a DNA binding
domain that interacts specifically with DNA target
sequences. The domain in the C-terminal region enables
oligomerization of p53 protein, which binds to DNA as a
tetramer. Since wt p53 is a critical tumor suppressor gene,
it is inactivated in many human cancers [23]. Interest-
ingly, inactivation of wt p53 often occurs as single point
mutation in the core DNA binding domain, suggesting
the importance of DNA binding for the tumor suppressor
function of wt p53. These mutations of the p53 DNA
binding domain can be divided into two groups [24].
Structure mutations are amino acid residue changes that
cause perturbation of the structure of the DNA binding
surface of p53 protein. Most common p53 structure muta-
tions appear in codons R175, G245, R249, and R282 [24].
Contact mutations are replacements of amino acid resi-
dues that normally make direct contact with the DNA.
Common p53 contact mutants include codons R248,
R273, and R280 [24]. In 15–30% of breast cancers, inacti-
vation of p53 occurs by mutation, making this the most
common genetic defect related to a single gene [25-28].
Microarray analyses have demonstrated that accumula-
tion of mutant (mt) p53 indeed causes changes in the
expression of a variety of genes, and indicates it still may
affect gene transcription [29-33]. Chromatin immunopre-
cipitation experiments have shown that mt p53 can bind
the promoter regions of genes in vivo; however, efforts to
identify mt p53 specific DNA-binding response elements
have failed [32-34].
In the present study, we investigated DNA-binding and
epigenetic modifications in response to induced levels of
wt and mt/wt p53 using non-malignant hTERT immortal-
ized human mammary epithelial cells (HME1). To simu-
late a wt p53 response, we used transient adenoviral
infection of wt p53. To determine the effect of mt p53 on
wt p53 we created four stable cell lines over-expressing the
R175H, R249S, R273H, and R280K p53 mutants in a wt
p53 background [35]. These p53 mutants were chosen
because they represent some of the most common p53
mutations forming together over 13% of all p53 mutation
cases identified in breast cancer [36]. Both methods of
p53 overexpression resulted in comparable levels of mt/
wt or wt p53 protein. To identify p53 binding sites in
these scenarios and p53's effect on the epigenetic state, we
conducted chromatin immunoprecipitation coupled to
microarray hybridization that analyzed 13,000 human
gene promoters.
Our study is unique from previously published results in
the fact that it analyzes not only binding of wt but also the
binding of mt/wt p53 on a genome wide scale. Previous
studies analyzed either only wt p53 binding on a genome
wide scale [15,16,18-20] or binding of selected p53
mutants to a few selected p53 target gene promoters [8].
To our knowledge, our study is also the first to identify the
changes in histone acetylation induced by wt or mt/wt
p53 on a genome wide scale. Moreover, our model exam-
ines this role of p53 in the context of non-malignant
mammary epithelial cells, in contrast to the malignantly
transformed colon, lung and osteosarcoma cells used in
previous studies. Taken together, this mt/wt p53 model
provides new insights into p53 dysfunction during an
early point in human mammary carcinogenesis when mt
p53 mutation coexists with wt p53.
Our results show that wt p53 binds a multitude of pro-
moter sequences causing increases in histone H3 and H4
acetylation. Some of these promoter sequences belong to
novel, previously undescribed, p53 target genes. This
DNA-binding and increase in histone acetylation in
response to wt p53 is associated with increases in gene
expression. We did not find any direct wt p53 binding
associated with decreases in histone acetylation or gene
expression. In the mt/wt p53 state over 95 % of p53 spe-
cific DNA binding was inhibited. The loss in p53 binding
resulted in very little change in histone H3 and H4
acetylation and no changes in DNA methylation. The
results of our investigation demonstrate a lack of wt p53
repressive binding and mt p53 DNA-binding as a whole.
Our data suggests that wt p53 DNA-binding is associated
with increased histone acetylation and gene expression of
a multitude of target genes, including several new wt p53
targets.
Results
Cell line treatments
Direct binding of p53 to target promoters and the effect of
over-expression of wt and mt p53 on the epigenetic state
of promoters was studied in a non-malignant hTERT
immortalized breast epithelial cell line, HME1. Wt p53 isBMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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toxic when overexpressed in these cells; therefore the
attempt to prepare cell lines stably overexpressing wt p53
was not successful. Thus, transient overexpression of wt
p53 from an adenoviral vector was used to induce a wt
p53 response and the level of p53 expression was consist-
ent with a physiological stress response. The p53 mutants
R175H, R249S, R273H and R280K were stably overex-
pressed in HME1 cells containing endogenous wt p53 to
analyze the effect that mt p53 had on wt p53's function as
a transcription factor. We have shown previously that wt
p53 accumulated in response to mt p53 overexpression in
these cells [35], and the accumulation of wt p53 likely
occurred due to stabilization as a result of its interaction
with mt p53 [35]. The combined level of wt and mt p53
protein in these cell lines was comparable to the level of
wt p53 in cells overexpressing wt p53 from the adenoviral
vector [35]. The cell lines created and used within the
study described in this paper are summarized in Table 1.
Genome-wide p53 promoter binding
First, we identified p53 binding to DNA targets using a
ChIP on chip method. The DO-1 monoclonal antibody,
which is targeted against amino acids 21–25 of p53 pro-
tein and recognizes both the wt and mt p53 proteins, was
used in our study. DNA from chromatin immunoprecipi-
tated by the DO-1 antibody was labeled and hybridized to
a 13,000 human gene promoter microarray. The probes
on this microarray represent 13,000 human gene promot-
ers and are PCR products that cover the regions 700 base
pairs upstream to 200 base pairs downstream of transcrip-
tion start [37]. Input DNA, i.e. DNA from unimmunopre-
cipitated chromatin, was co-hybridized as a reference.
DO-1 immunoprecipitation from MDA-MB-157 cell line
that has p53 null phenotype and does not express p53
protein detectable by western blot (data not shown) was
used as the other reference.
The parental HME1 cell line with basal levels of wt p53
showed no significant p53 binding to any of the promot-
ers on the microarray (Fig 1A). In contrast, HME1 cells
with transiently overexpressed wt p53 (Ad5WT) exhibited
significant binding to a variety of different gene promot-
ers. Wt p53 in these cells was found to bind to 197 pro-
moters, which represents nearly 2% of the analyzed
promoters (Fig 1A). The bound promoters included many
known p53 transcriptional targets such as PLK3,  FAS,
APAF1,  C12orf5,  PCNA,  TP53INP1,  DDB2,  MASPIN,
GDF15 and PIG11. In addition to known p53 targets there
was a group of gene promoters with significant binding
that had not been previously described as p53 targets.
These genes, which include FBXO22, DGKZ, MGC4771,
PCM1, GDF9, DPAGT1, SKI, SYK, OVOL1 and PLXNB3,
were identified as potential novel p53 targets. The total list
of wt p53 bound promoters is provided in additional file
1
Expression of mt p53 protein on the wt p53 HME1 back-
ground inhibited DNA binding. Despite the high level of
wt p53 protein in cells overexpressing mt p53, the pres-
ence of mt p53 led to a greater than 95% reduction in p53
binding to its targets. The cell line with overexpressed mt
R175H showed no promoter binding. p53 in the remain-
ing three cell lines overexpressing R249S, R273H and
R280K mt p53 bound to only 3, 5 and 23 promoters on
the microarray, respectively (Fig 1A). The promoters
bound in R273H and R280K significantly overlap with
promoters bound in the wt p53 only expressing cell line
(Ad5WT). All overlaps between p53 binding in mt/wt
samples and p53 binding in Ad5WT sample with respec-
tive probabilities that overlaps are just random were 1
promoter for R249S (p-val = 5.6 × 10-2), 3 promoters for
R273H (p-val = 6.6 × 10-5) and 7 promoters for R280K (p-
val = 1.5 × 10-7) (Fig 1A). The list of promoters bound by
mt/wt p53 is shown for each mutant in additional file 1.
A substantial number of promoters bound by the mutants
Table 1: Cell line models used in this study
Name mutated codon mutation amino acid change vector promoter overexpression p53 phenotype
HME1 None none none none none none wt parental
Ad5WT None none none Adenovirus CMV transient (24h) wt accumulated
R175H 175 GCG→GCA Arg→His Lentivirus CMV stable mt/wt accumulated
R249S 249 AGG→AGC Arg→Ser Lentivirus CMV stable mt/wt accumulated
R273H 273 GCG→GCA Arg→His Lentivirus CMV stable mt/wt accumulated
R280K 280 GAG→GAA Arg→Lys Lentivirus CMV stable mt/wt accumulated
The table displays the names of samples used within this study, mutated codon position and nucleotide and amino acid change in p53 if any, vector 
and promoter used for p53 variant overexpression, type of overexpression and p53 phenotype of the studied cell lines.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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were not detected as bound in the Ad5WT cells (Fig. 1A).
These data suggest that the presence of mt p53 inhibits the
binding of wt p53 to its targets, and possibly allows for
binding to non-target sites. Further study revealed that
p53 in the R280K mt binds only promoters with a high
level of histone acetylation (Fig 1B). Our data indicate
that wt p53 at basal levels does not bind its target sites and
that the presence of a mt p53 can block elevated levels of
wt p53 from binding target promoters.
Genome-wide assessment of epigenetic modifications 
induced by p53 binding
Since a number of p53 targets become epigenetically
silenced in cancer, we tested whether p53 overexpression
invokes epigenetic changes such as altered acetylation of
histones H3 and H4 and methylation of DNA. For histone
acetylation the chromatin was immunoprecipitated using
antibodies against acetylated histones H3 or H4 as two
independent marks of changes in chromatin. DNA from
immunoprecipitated samples was labeled and hybridized
to the 13,000 human gene promoter microarray using
input DNA as a reference. The changes in histone acetyla-
tion relative to parental and vector only transformed cell
lines were calculated. Most significant changes in histone
acetylation occurred in response to overexpression of wt
p53. Histone H3 became significantly more acetylated in
79 promoters and significantly less acetylated in 30 pro-
moters in this sample (Fig 2A). Acetylation of histone H4
increased in 162 promoters and decreased in 30 promot-
ers in response to wt p53 (Fig 2B). The total list of differ-
entially acetylated promoters is available as additional file
2.
A different situation was observed in the mt p53 express-
ing cell lines. The only mt cell line with a significantly
changed histone H3 acetylation pattern was R175H with
22 promoters with increased acetylation and 41 promot-
ers with decreased acetylation. The histone H3 acetylation
in the remaining three mt p53 cell lines was similar to the
parental cell line. The R249S showed no significant
changes, R273H had 3 promoters with increased and 2
promoters with decreased acetylation, and R280K had 1
promoter with decreased acetylation (Fig 2A). Similar
results were obtained for acetylation of histone H4 (Fig
2B). Interestingly, the mt R280K that demonstrated the
most DNA binding of all mutants, had nearly no effect on
histone acetylation, and bound only to promoters that
were already highly acetylated (Fig 1B).
In order to determine if mt p53 alters DNA methylation
state, DNA methylation was analyzed using two microar-
ray platforms. One platform was a 6,800 element CpG
island microarray. This DNA microarray contains ds DNA
probes that cover CpG rich regions dispersed throughout
the human genome, including single copy regions as well
Numbers of p53 bound promoters in studied cell lines Figure 1
Numbers of p53 bound promoters in studied cell 
lines. The number of promoters bound by p53 in the studied 
cell lines and their average acetylation detected by chromatin 
immunoprecipitation and hybridization to 13,000 human 
gene promoter microarray. The left panel displays number of 
promoters bound by p53 and their overlap between samples. 
Data are from three independent experiments including dye 
swap, therefore six hybridizations per sample. Promoters 
that have shown enrichment over both input and p53 null 
reference (MDA-MB-157) samples at p-value 0.01 or lower 
were considered bound. The cell line labels, numbers of pro-
moters bound in each cell line, and numbers of promoters 
bound in each cell line that overlap with those bound in 
Ad5WT are displayed below the x-axis. The numbers of pro-
moters are represented by the y-axis. The black boxes are 
promoters bound by p53 in a particular cell line. Only pro-
moters bound by p53 in at least one cell line are shown. The 
total list of p53 bound promoters is available as additional file 
1. The right panel displays the average acetylation of histones 
H3 and H4 in promoters displayed on the left panel. The 
level of acetylation is repreresented by a heatmap. Green 
color reflects higher acetylation, red color lower acetylation. 
The block of only highly acetylated promoters corresponding 
to promoters bound by R280K mt p53 is clearly visible.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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as alu and satellite repeat elements [38]. The other plat-
form was the 13,000 human gene promoter microarray
used for the p53 binding and histone acetylation study.
DNA samples from each of the four mt p53, parental
HME1 and vector only transformed cell lines were ana-
lyzed using a McrBC digestion technique and hybridiza-
tion to the CpG island microarray. No significant changes
in DNA methylation state in response to long-term mt
p53 overexpression were found (data not shown). To ver-
ify these observations, DNA from parental HME1, vector
only, and the R175H mt cells which demonstrated the
most changes in histone acetylation, was immunoprecip-
itated with a 5-methylcytosine specific antibody. Labeled
DNA was hybridized to the 13,000 human gene promoter
microarray against input DNA as a reference. No signifi-
cant changes in DNA methylation were found (data not
shown).
Our data suggest that overexpression of wt p53 affected
histone acetylation of a multitude of gene promoters. The
expression of mt p53 forms did not have an effect on his-
tone acetylation, with the exception of the R175H mt.
This p53 mutant, however, does not bind DNA at all, so
the observed changes were likely an indirect effect of
expression of R175H mt p53 protein in the cell. Despite
changes in acetylation of histones in R175H mt, we did
not find significant changes in DNA methylation in any
mutant expressing cell lines. The methylation of DNA in
the cell line overexpressing wt p53, which is harvested a
short time after infection (24 h), was not determined
because earlier results suggest that DNA methylation does
not change in such a short time frame [39].
Changes in acetylation in response to wt p53 binding
The only cell line that showed a significant number of p53
bound promoters and changes in histone acetylation was
HME1 overexpressing wt p53 (Ad5WT). Therefore, we
studied whether there is an overlap between the promot-
ers that were bound by wt p53 and those whose acetyla-
tion has changed in these cells. These data are
summarized in figure 3. Approximately 20 % (41 out of
197, Fig 3) of the promoters bound by wt p53 had signif-
icant changes in acetylation of histone H3 or H4. This
overlap is highly significant, i.e. there exists a correlation
Figure 2
Changes in acetylation of histones H3 and H4 in studied cell  lines Figure 2
Changes in acetylation of histones H3 and H4 in stud-
ied cell lines. Heatmaps show histone acetylation status of 
promoters that demonstrate significant changes from control 
(parental and vector only transformed) cell lines in any sam-
ple detected by chromatin immunoprecipitation and hybridi-
zation to 13,000 human gene promoter microarray. 
Promoters were sorted in the y-axis direction by decreasing 
average acetylation. Green color reflects high acetylation, 
red color low acetylation. The average acetylation from 
three independent experiments is shown. Cell line labels are 
displayed below the x-axis. The two bottom lines display the 
number of promoters that were significantly (p-val ≤ 0.05) 
more or less acetylated than in the control cell lines, and are 
shown by black dots within the figure. Acetylation of histone 
H3 is shown on the left and acetylation of histone H4 on the 
right. The total list of differentially acetylated promoters is 
available as additional file 2.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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between promoters bound by p53 and those with
changed acetylation, the p-value of this overlap is lower
than 2.2 × 10-16. Therefore we conclude that a correlation
exists between wt p53 DNA binding and changes in his-
tone acetylation. The majority of these promoters (40 out
of 41) had increased histone acetylation, consistent with
wt p53 as a transcriptional activator.
p53 binding and expression analysis using real-time PCR
To verify the microarray p53 binding data, real-time PCR
was performed to validate and determine the level of
enrichment of selected promoter sequences in immuno-
precipitated samples. We tested the promoters of 25 genes
and GAPDH as a negative control. The greatest enrich-
ment over input was demonstrated by the promoter of the
gene PLK3 (11.7 fold, Fig 4). This is consistent with micro-
array binding data where this promoter reached the low-
est p-value (5.24 × 10-18) for enrichment over input. No
positive promoters were confirmed by real-time PCR
when the p-value was > 0.01 (Fig 4 left panel). This data
suggests that the p-value used to decide whether a pro-
moter is bound by p53 or not is appropriate.
Because p53 binding is likely to change the expression of
its target genes, the expression of selected genes was stud-
ied using real-time RT-PCR. Most of the tested genes
shared an increase in expression from 2 fold (MASPIN) up
to 246 fold (GDF9) over control in response to wt p53
overexpression (Fig 5). p53 binding data, changes in his-
tone acetylation of histones H3 and H4 and changes in
expression for 13 selected genes bound by wt p53 accord-
ing to the ChIP on chip analysis are summarized in Table
2. These genes include previously known p53 targets such
as APAF1, FAS, PLK3 and MASPIN and several genes that
were not previously described as p53 transcriptional tar-
gets. The new p53 targets include FBXO22, DGKZ, GDF9,
SYK, and PLXNB3.
Overlap between wt p53 DNA binding and changes in his- tone acetylation Figure 3
Overlap between wt p53 DNA binding and changes 
in histone acetylation. The Venn diagram shows the over-
lap between promoters bound by wt p53 and promoters 
with significant changes in acetylation of histones H3 and H4 
in response to wt p53 overexpression. The number of pro-
moters with increased acetylation are marked with a (+) sign 
and those with decreased acetylation with a (-) sign.
Real-time PCR verifies wt p53 binding detected by microar- ray analysis Figure 4
Real-time PCR verifies wt p53 binding detected by 
microarray analysis. The left panel displays the significance 
level of p53 binding to selected promoters according to the 
microarray data. The x-axis displays log(p-value) of enrich-
ment over input. The vertical dashed line shows the p-value 
0.01 which was used as a limit. The right panel depicts fold 
enrichment of p53 bound promoters as detected by chroma-
tin immunoprecipitation and real-time PCR. The x-axis dis-
plays fold enrichment of immunoprecipitated sample over 
input. The vertical dashed line shows the level of the negative 
control gene GAPDH, which is not enriched. The genes that 
had significant increases in expression are marked with an 
asterisk.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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Our data suggest that epigenetic changes, such as acetyla-
tion of histones H3 and H4 are induced in response to
overexpression of wt p53 and some p53 mutants in the
breast epithelial cell model system, but DNA methylation
is not affected by the presence of mt p53. This study also
identified several new, previously undescribed, transcrip-
tional targets of wt p53.
Discussion
We describe in this report the DNA binding capacity, his-
tone acetylation changes, and DNA methylation changes
in response to wt p53 accumulation alone and wt p53
accumulation that occurs with overexpression of mt p53.
We had previously demonstrated that overexpression of
exogenous mt p53 by lentiviral stable insertion caused a
concomitant increase in endogenous wt p53 in HME1
cells [35]. This accumulation of endogenous wt p53
occurs as a result of interaction with the more stable mt
p53 protein. The wt and mt p53 molecules form heterote-
tramers and the average ratio of wt and mt p53 in these
heterotetramers was 1:1 [35]. Therefore, this report
describes the binding and transactivation effects of wt p53
alone, as well as mt/wt p53 heterotetramers, which would
simulate a heterozygous mt/wt state.
Mutations of the p53 DNA binding domain can be
divided into two groups [24]. Structure mutations are
amino acid residue changes that cause perturbation of the
structure of the DNA binding surface of p53 protein. Con-
tact mutations are replacements of amino acid residues
that normally make direct contact with the DNA. Accord-
ing to this classification, of the 4 mt p53 investigated in
our study, R175H and R249S are structure mutations
whereas R273H and R280K are contact mutations.
The structure mt R175H did not show any DNA binding
on our promoter microarray, and we conclude that the
altered conformation of this mt p53 protein likely affects
the conformation of the entire mt/wt heterotetramer and
completely compromises its binding to DNA. The changes
in histone acetylation we observed in this mt are therefore
most likely the secondary effects of overexpression of mt
p53 protein and not a direct effect of mt p53 binding to
DNA. The mt protein with changed structure possibly
forms new interactions with other proteins. Effect of
R175H mt could be also caused by preventing the binding
of wt p53 to sites that are occupied under normal condi-
tions. However, the relative occupancy of p53 target sites
in untreated HME1 cells is so low, if any, that it was not
detected by our ChIP on chip analysis as statistically sig-
nificant.
The structure mt R249S bound only 3 promoters (only 1
of these promoters was bound in Ad5WT sample) and did
not invoke any changes in histone acetylation. The con-
tact mt R273H bound 5 promoters (3 of them were bound
in Ad5WT) and induced nearly no changes in histone
acetylation. The R249S and R273H mutants severely com-
promised p53 DNA binding, only allowing 1–2% of wt
p53 binding. This data likely explains why we did not
detect many changes in histone acetylation in these two
cell lines.
The contact mt R280K retained the highest DNA binding
of the four mutants tested in our study. Interestingly, it
bound only to promoters with a high basal level of his-
tone acetylation and many of these targets appear to be
non-specific as they were not bound by wt p53. This
observation suggests that this p53 mt has altered DNA
binding activity and prefers regions of highly acetylated
histones, i.e. actively transcribed chromatin. This binding
is probably not specific to any particular target DNA
Real-time RT-PCR demonstrates increased expression of  genes bound wt p53 Figure 5
Real-time RT-PCR demonstrates increased expres-
sion of genes bound wt p53. The bar graph depicts real-
time RT-PCR detection of changes in expression in response 
to wt p53 overexpression. 15 selected genes whose promot-
ers were found to be bound by wt p53 are displayed with 
GAPDH as a negative control. The y-axis is in logarithmic 
scale and displays fold change in expression relative to con-
trol cell line. The horizontal dashed line shows the relative 
level of expression in the control sample. The data were nor-
malized relative to GAPDH. The error bars display the stand-
ard error of three replicates.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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sequence. Additionally, binding of this mutant did not
cause many changes in histone acetylation, possibly
because of the fact that it bound only promoters that were
already highly acetylated.
Of the four mutants tested in our study, the structure
mutants R175H and R249S had more compromised DNA
binding than the contact mutants R273H and R280K. This
could be the result of more severe changes in protein
structure. However, the level of p53 protein in cells over-
expressing the structure mutants R175H and R249S was
about 2/3 that seen in the R273H and R280K [35]. So,
lower levels of p53 protein causing lower DNA binding
can not be completely excluded. Nonetheless, our experi-
mental data show that the binding of p53 in the four
mutant expressing cell lines was highly compromised in
comparison with binding of wt p53.
We detected significant increases and decreases in histone
acetylation in response to wt p53 overexpression. How-
ever, consistent with wt p53 function as a transcriptional
activator, we found mostly increases in histone acetyla-
tion overlapping p53 binding. This overlap between pro-
moters that were bound by wt p53 and those that showed
significant increases in acetylation of either histone H3 or
H4 was highly significant. The overlapping group, how-
ever, formed only about 20% of the bound promoters.
The remaining 80% of the bound promoters showed no
significant changes in acetylation, however, most of these
promoters were already highly acetylated in untreated
cells so that a further increase due to p53 binding was
impossible or undetectable as significant.
The high proportion of promoters with increase in his-
tone acetylation without p53 binding (Fig 3) may be due
to the limited region covered by microarray probes. p53
can bind much further upstream than the region covered
by the probes on the promoter microarray (700 bp
upstream to 200 bp downstream of transcription start).
For example p21, one of the best known p53 responsive
genes, has two p53 binding sites located 2.3 and 1.4 kbp
upstream of transcription start [40]. Therefore, the micro-
array used in this study is able to detect changes in acetyla-
tion in the transcriptional start regions of such genes, but,
Table 2: Summary of data for select known and novel wt p53 targets
gene name binding p-value enrichment microarray enrichment real-time PCR H3 H4 expression change
PLK3 5.24E-18 2.3 11.7 1.7* 2.0* 2.7
FAS 1.26E-16 1.9 6.6 1.1 1.1 2.9
APAF1 9.04E-16 1.5 3.2 1.4* 1.3 3.7
FBXO22* 9.64E-14 1.6 6.1 1.3* 1.2 3.1
DDB2 1.19E-10 1.3 4.2 1.1 1.0 3.4
DGKZ* 1.12E-09 1.5 4.5 1.8* 1.7* 2.1
MASPIN 4.81E-08 1.2 5.4 1.3* 1.1 1.9
SEMA3B 2.31E-07 1.2 3.6 1.4 1.3 14.3
GDF9* 7.69E-06 1.3 2.4 1.2* 1.2 246.1
SYK* 1.33E-04 1.2 1.6 1.1 1.0 3.7
CSPG2 1.38E-04 1.1 1.5 1.5* 1.3* 8.6
PLXNB3* 3.81E-04 1.2 1.6 1.4* 1.1 9.4
RPS27L 1.58E-03 1.2 4.8 1.4 1.3* 4.0
Novel direct p53 target genes are marked with an asterisk. The p-value column displays the p-value of enrichment of p53 ChIP sample over input 
detected by the microarray. The next two columns display fold enrichment of ChIP sample over input detected by microarray hybridization or real-
time PCR, respectively. The histone H3 and H4 columns display fold changes in histone acetylation relative to the control cell lines. Significant 
changes (p-val ≤ 0.05) in histone acetylation are marked with an asterisk. The expression column displays fold increase in expression, detected by 
real-time RT-PCR, relative to control.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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if p53 binding occurs several kbp up or down stream, this
microarray could not detect this event. Finally, many
genes with changed acetylation without detected p53
binding may also be secondary targets, downstream on
the p53 regulated response pathway.
With one exception, we have not detected any significant
decreases in histone acetylation for the promoters bound
by p53. These results are not in complete agreement with
other published in some other studies [9-11] where a
decrease in histone acetylation was observed at some p53
target genes. This apparent discrepancy could be due to
differences in models employed (malignant versus non-
malignant cells, cell types analyzed), the fact that not all
transcriptional down regulation is linked to histone
deacetylation, and the different analytical tools employed
in the individual studies. For example, using a DNA
sequencing strategy, Wei et al [19] observed that the p53
binding sites of genes that are transcriptionally activated
tend to cluster around the transcriptional start of the gene.
By extension p53 binding sites in targets of transrepres-
sion may have a tendency to occur at regions removed
from promoter regions, and therefore would not be
detected by the human gene promoter microarray we
employed. Alternatively, p53 transrepression and associ-
ated histone deacetylation may occur through protein-
protein interactions that do not involve direct binding of
p53 to DNA [10], and therefore would not be effectively
detected using ChIP-based approaches.
Our study revealed several potential new p53 target genes.
We have tested the expression of selected candidates in
response to p53 overexpression by real-time RT-PCR.
According to our data, the genes SYK, GDF9, DGKZ, and
FBXO22 are direct p53 targets demonstrated by ChIP on
chip analysis and realtime RT-PCR analysis, which have
not been described before. There are numerous studies
suggesting that SYK (spleen tyrosine kinase) acts as a
tumor suppressor in breast cancer and human melanoma
as its overexpression inhibits invasiveness of both types of
tumors [41-44]. GDF9 (growth differentiation factor 9)
has been shown to reduce the invasiveness of breast can-
cer cells [45]. Suggesting that SYK and GDF9 are tumor
suppressor genes is consistent with our observation that
they are direct p53 transcriptional targets. DGKZ (diacylg-
lycerol kinase zeta) binds pRB and overexpression of
DGKZ in pRB-null fibroblasts reconstitutes a cell cycle
arrest induced by gamma-irradiation [46]. Participation
in cell cycle arrest is consistent with being a p53 target.
FBXO22 (F-box protein 22) belongs to the family of f-box
proteins [47] which are one of the four subunits of ubiq-
uitin protein ligases. F-box proteins thus comprise the
specificity of substrate for ubiquitination. The FBXO22
could, therefore, be involved in degradation or inactiva-
tion of specific proteins in response to p53 induction.
Therefore we conclude that the novel p53 targets have
functions consistent with the tumor suppressive activity of
their regulator wt p53.
Overall, we observed binding of induced wt p53 to almost
two hundred gene promoters including known and novel
wt p53 targets. Binding of wt p53 in about 20% of cases
was accompanied by increased histone acetylation fol-
lowed by increased expression. We did not observe any
significant decreases in histone acetylation directly driven
by wt p53 binding. The mt p53 highly compromised p53
binding to DNA when expressed on a wt p53 background.
Therefore, there were no direct changes in histone acetyla-
tion and no changes in DNA methylation observed in
these cell line models.
Conclusion
Wt p53 when overexpressed from adenoviral vector in
HME1 cells bound 197 promoters of the human gene pro-
moter microarray. p53 binding resulted in statistically sig-
nificant increases in histone acetylation of either histone
H3 or histone H4 or both for 40 of these promoters. We
observed no decreases in histone acetylation for genes
bound by p53, so we conclude that wt p53 targets are
biased towards gene activation. From these studies we
identified and validated a number of new direct transcrip-
tional targets of wt p53 including DGKZ, FBXO22 and
GDF9.
The p53 mutants R175H, R249S, R273H, and R280K,
when overexpressed in HME1 cells with a wt p53 back-
ground, showed no or highly compromised DNA binding
relative to a comparable level of wt p53 alone. This sup-
ports a dominant negative effect of mt p53 on the wt p53
protein. There were very few changes in histone acetyla-
tion observed in cells overexpressing mt p53 with the
most occurring in the R175H mutant. We observed no
changes in DNA methylation in response to long-term
expression of mt p53. In summary the mt p53 inhibited
binding of wt p53 resulting in blocking of wt p53 epige-
netic actions.
Methods
Cell culture
The cell lines hTERT-HME1 and MDA-MB-157 were pur-
chased from the American Type Culture Collection (Rock-
ville, MD, USA). The hTERT-HME1 cell lines harboring mt
p53 genes were prepared in our lab previously and their
cultivation was previously described [35]. The MDA-MB-
157 cells were cultured as previously described [39].
Recombinant adenovirus serotype 5, containing wild-type
p53 with a green fluorescent protein marker, was the kind
gift of Bert Vogelstein and was propagated as previously
described [39]. Adenovirus was added to hTERT-HME1
cells at 100 pfu/cell for 24 hours.BMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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Chromatin immunoprecipitation (ChIP)
A previously described ChIP protocol was used [48],
except that the final purification of immunoprecipitated
samples was done using a QIAquick® PCR purification kit
(Qiagen, Valencia, CA, USA) instead of phenol/chloro-
form extraction. p53 specific ChIP was performed using 2
μg of antibody clone DO-1 (Ab-6, #OP43, Calbiochem,
EMD Chemicals, La Jolla, CA, USA) per 1.2 mL of diluted
lysate from 107 cells. ChIP of acetylated histones H3 and
H4 using antibodies against acetylated histones H3 (rab-
bit polyclonal IgG, #06-599, Upstate Biotech, Lake Placid,
NY, USA) and H4 (rabbit polyclonal serum, #06-866,
Upstate Biotech) were perfomed as previously described
[39]. Immunoprecipitated DNA was quantified using
PicoGreen dye (Invitrogen, Carlsbad, CA, USA) and
BioTek FLx800 Multi-Detection Microplate Reader
(BioTek Instruments, Winooski, VT, USA).
Microarray detection of p53 binding, histone acetylation 
and DNA methylation
The human promoter microarray used in our study con-
tains PCR fragments targeted to regions spanning 700 bp
upstream and 200 bp downstream of the transcription
start sites of 13,000 human genes. Primers for the micro-
array probes were obtained from the Whitehead Institute
[37] and microarray preparation was described earlier
[35].
For microarray analysis DNA was first amplified using the
BioPrime DNA Labeling System (Invitrogen) with 1 mM
dTTP used instead of labeled dUTP. Equal amounts (1 μg)
of amplified ChIP and input DNA were labeled using the
BioPrime DNA Labeling System with Cy3 or Cy5 dyes
respectively using a double reaction per sample and 1/3
the recommended amount of dye. Cy3 and Cy5 labeled
targets were mixed, then 20 μg of human Cot-1 DNA (Inv-
itrogen) and 40 μg of yeast tRNA (Invitrogen) were added,
and samples were dried under vacuum. Targets were dis-
solved in DMH-25 Domino Oligo Hybridization Buffer
(The Gel Company, San Francisco, CA, USA), denatured
and hybridized to processed microarray slides using an
ArrayBooster (Advalytix, Munich, Germany) at 42°C for
16 h. Following hybridization, slides were washed with 2×
SSC, 0.1% SDS for 5 min, then with 0.06× SSC, 0.1% SDS
for 5 min, and finally with 0.06× SSC for 5 min, all at
room temperature. Slides were scanned for Cy3 and Cy5
fluorescence using an Axon GenePix 4000 microarray
reader (Axon Instruments, Inc., Foster City, CA, USA).
Detailed amplification, labeling and hybridization proto-
cols and microarray data are available in the ArrayExpress
database: p53 binding [ArrayExpress:E-MEXP-1491], his-
tone H3 acetylation [ArrayExpress:E-MEXP-1493] and his-
tone H4 acetylation [ArrayExpress:E-MEXP-1494].
For 5-methylcytosine DNA analysis, DNA was immuno-
precipitated using 2 μg/sample mouse monoclonal anti-
body 33 D3 (#AMM99021, Aviva Systems Biology, San
Diego, CA, USA) specific for 5-methylcytosine DNA as
previously described [49] and further analyzed on the
promoter microarray. McrBC digestion analysis of DNA
methylation and CpG island microarray hybridization
was conducted as previously described [38].
Statistical analysis of microarray data
The data from scanned microarray images were extracted
using GenePix software and further analyzed using the
limma package [50] for R [51]. p53 binding experiments
were done in triplicate using dye swap for each replicate
resulting in 6 hybridizations per cell line. Microarrays
were normalized using loess function for within array nor-
malization and quantile function for between array nor-
malization. Finally, two linear model fits were calculated
using inputs or MDA-MB-157 negative control ChIP sam-
ples as the common references, respectively. A list was
generated of promoters that were enriched in the studied
cell lines over both input and over MDA-MB-157 negative
control at p-value ≤ 0.01. These promoters are referred to
as bound by p53 within this paper. Acetylation of histones
H3 and H4 and DNA methylation experiments were done
in triplicate. A linear model fit was computed using input
as a common reference. Contrasts of p53 over-expressing
cell lines relative to control (parental and vector only
transformed cells) were calculated using p-value ≤ 0.05.
The significance of gene list overlaps was calculated using
R as described previously [52].
Real-time PCR
Equal amounts (1 ng) of p53 specific ChIP and input
DNA were used for real-time PCR analysis. Primers were
designed for potential p53 binding sites in promoter
regions covered with probes on the promoter microarray
for the genes PLK3, FAS, APAF1, FBXO22, DDB2, DGKZ,
MASPIN,  MGC4771,  SEMA3B,  PCM1,  GDF9,  DPAGT1,
SKI,  SYK,  CSPG2,  OVOL1,  PLXNB3,  TSSC4,  NR1H3,
RPS27L,  EVA1,  ITPKB,  ICT1,  VSNL1,  PRKAB2, and
GAPDH. Primers were designed for use with the Human
Universal Probe Library Set (Roche Diagnostics, Indiana-
polis, IN, USA). Real-time PCR was conducted on an ABI
Prism 7500 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA) using PerfeCta qPCR Super-
Mix, Low ROX (Quanta Biosciences, Gaithersburg, MD,
USA) with a 95°C denaturation for 3 minutes followed by
45 cycles of 95°C for 15 seconds and 60°C for 45 sec-
onds. Enrichment was calculated as previously described
[39]. Primer sequences are available upon request.
Real-time RT-PCR
Total RNA was isolated using the RNeasy® Mini Kit (Qia-
gen). Reverse transcription was performed as previouslyBMC Genomics 2008, 9:486 http://www.biomedcentral.com/1471-2164/9/486
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described [39]. Primers were designed for PLK3,  FAS,
APAF1,  FBXO22,  DDB2,  DGKZ,  MASPIN,  MGC4771,
SEMA3B,  GDF9,  SYK,  CSPG2,  PLXNB3,  RPS27L,  EVA1
and GAPDH and used with the Human Universal Probe
Library Set (Roche Diagnostics). PCR was run using cDNA
generated from the equivalent of 15 ng of RNA per reac-
tion as described above. All experiments were conducted
in triplicate from three independent RNA isolations.
Primer sequences are available upon request.
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